Sanofi, AstraZeneca mark big leap toward filing of RSV drug in 2022, with safety data in hand to challenge Synagis

In a Phase II/III trial involving babies who were born preterm or had chronic lung disease or congenital heart disease, the partners said, nirsevimab showed a similar safety and tolerability profile compared to Synagis — the standard and only drug currently available for the same group. They are eyeing a filing in the first half of 2022.